publication date: Dec. 19, 2010

In this issue: 

Avastin improves lung cancer survival, opens options for new combinations. Details of Avastin risk vs. benefit to be released at ASCO annual meeting.

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

Download (PDF 389KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.